Chikungunya is a mosquito borne infectious disease causing long term, debilitating, arthritis like symptoms and death in severe cases. Climate change has increased in the home range of the formerly tropical mosquito vector, it can now potentially be found as far north as New York, and as far south as Sydney.
With severe morbidity, outbreaks on the increase, and an extensive geographical distribution of the virus, a Chikungunya Vaccine is greatly needed.
Sementis’ is working on a preventative vaccine for Chikungunya, based upon its proprietary SCV Vector System.
Details of our SCV-chikungunya vaccine preclinical proof-of-concept studies can be found in the follow publication that can be downloaded from:
SCV-CHIK proof-of-concept vaccination study demonstrated:
• A single vaccination with 106 infectious units (IU) stimulated elevated anamnestic anti-chikungunya antibody responses 4 weeks post vaccination that persisted 1 year later
• A single vaccination with 106 IU stimulated the production of anti-chikungunya neutralizing antibodies that could be detected 4 weeks after vaccination
• A single vaccination with 106 IU prevented spread of chikungunya virus via the blood vascular system during deliberate infection with infectious chikungunya virus
• A single vaccination with 106 IU prevented chikungunya virus inducing arthritis during deliberate infection with infectious chikungunya virus
• Vaccination prevented chikungunya infection from persisting
• 1 year after vaccination, long lived antibody secreting cells could be detected.
• Results are published in: Eldi etal (2017) Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology. Molecular Therapy; 25 (10): 2332-2344